Drugs Information:
Polatuzumab vedotin
Basic Information
|
||
| ID | DDInter1485 | |
| Drug Type | biotech | |
| Protein Chemical Formula | C6670H10317N1745O2087S40 | |
| Protein Average Weight | 150000.000 | |
| CAS Number | 1313206-42-6 | |
| Description | Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells.[L6658] The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable linker called maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl (mc-vc-PAB) that covalently attaches MMAE to polatuzumab.[L6658] Polatuzumab vedotin was granted accelerated FDA approval on June 10, 2019 [A254936] and was approved by Health Canada on July 9, 2020.[L44141] | |
| ATC Classification | L01FX14 | |
| Sequences | None | |
| Useful Links | DrugBank PubChem Substance Wikipedia | |
Interactions with
Polatuzumab vedotin
Filter:
| Severity level | ID | Name | Mechanism | Detail |
|---|
Interactions with diseases
Filter:
| Severity level | Disease name | Text | References |
|---|
Interactions with foods
Filter:
| Severity level | Food name | Description | Management | Mechanism | References |
|---|
Interactions with compound preparation
| Multi-DRUG trade | Multi-DRUG | Drug type | Warning | Note |
|---|